Pyogenic autoinflammatory syndrome

Pyogenic autoinflammatory syndrome, also known as pyogenic autoinflammatory disease, is a group of rare hereditary autoinflammatory disorders characterized by recurrent episodes of sterile (non-infectious) pyogenic inflammation affecting multiple organ systems. These conditions are driven by dysregulation of the innate immune system, leading to excessive inflammatory responses without an identifiable infectious trigger. The term encompasses several specific entities, including pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome), as well as related conditions such as PAPA-like syndromes. Clinically, patients typically present with recurrent fevers, sterile abscesses, destructive pyogenic arthritis (joint inflammation with pus formation), and skin manifestations including pyoderma gangrenosum (deep ulcerating skin lesions) and severe cystic acne. The joints, skin, and bones are the most commonly affected organ systems. Onset is usually in childhood, and the disease follows a relapsing-remitting course. The inflammatory episodes can cause significant tissue damage over time, particularly joint destruction if inadequately treated. Treatment is aimed at controlling inflammation and preventing organ damage. Biologic therapies targeting interleukin-1 (IL-1) pathways, such as anakinra and canakinumab, have shown efficacy in many patients. Anti-TNF agents (such as infliximab or adalimumab) may also be used. Corticosteroids can provide short-term relief during flares but are not ideal for long-term management due to side effects. Early diagnosis and initiation of targeted anti-inflammatory therapy are important to minimize cumulative tissue damage and improve quality of life.

Common questions about Pyogenic autoinflammatory syndrome